title: Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
authors.forename: Iria
authors.initials: I
authors.lastname: Castiñeiras
authors.forename: Luisa
authors.initials: L
authors.lastname: Fernández-Diaz
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Juárez
authors.forename: Mercedes
authors.initials: M
authors.lastname: Lueiro
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003873:Dermatitis, Exfoliative / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab